ARWR Arrowhead Pharmaceuticals


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The following proposals were submitted to the stockholders of the Company at the Annual Meeting.

To elect the seven director nominees named in the Proxy Statement to serve as members of the Company’s Board of Directors until the next annual meeting or until their successors are elected;

To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers;

To approve the 2021 Plan; and

To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2021.

As of January 25, 2021, the record date for the Annual Meeting, the Company had 103,789,410 shares of its common stock outstanding and entitled to vote. At the Annual Meeting, 84,440,756 shares were present in person or represented by proxy and entitled to vote. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

Election of Directors

Christopher Anzalone61,950,096506,79621,983,864
Marianne De Backer60,595,5851,861,30721,983,864
Mauro Ferrari60,147,5572,309,33521,983,864
Douglass Given61,863,162593,73021,983,864
Adeoye Olukotun60,720,7571,736,13521,983,864
Michael S. Perry23,003,22039,453,67221,983,864
William Waddill60,677,4491,779,44321,983,864

Advisory Vote to Approve Executive Compensation

27,526,874 FOR 33,678,454 AGAINST 1,251,564 ABSTAIN 21,983,864 NON VOTES

Approval of the Company’s 2021 Plan

58,470,473 FOR 3,914,013 AGAINST 72,406 ABSTAIN 21,983,864 NON VOTES

Ratification of Rose, Snyder & Jacobs as Independent Auditors of the Company

82,918,788 FOR 1,352,478 AGAINST 169,490 ABSTAIN